More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.59B
EPS
-0.82
P/E ratio
--
Price to sales
421.22
Dividend yield
--
Beta
2.456709
Previous close
$10.08
Today's open
$11
Day's range
$9.32 - $11.25
52 week range
$2.24 - $11.25
show more
CEO
Sean Mcclain
Employees
156
Headquarters
Vancouver, WA
Exchange
Nasdaq Global Select
Shares outstanding
155905056
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Market Watch • 13 hours ago

ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research • Jun 25, 2026

ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
Zacks Investment Research • Jun 25, 2026

Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Absci Corporation (NASDAQ:ABSI) stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, while also pricing a $100 million underwritten stock offering to support continued development of the program.
Benzinga • Jun 24, 2026

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci
GlobeNewsWire • Jun 24, 2026

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts
GlobeNewsWire • Jun 24, 2026

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, “Partnering to Power the New Era of Drug Discovery,” will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr.
Business Wire • Jun 12, 2026

Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Seeking Alpha • Jun 10, 2026

Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Seeking Alpha • Jun 5, 2026

Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:
GlobeNewsWire • May 20, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Absci Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.